GSK

1,851.25

-2.33%↓

STJ

1,195

-2.05%↓

HIK

1,404.5

+1.08%↑

HILS

2,490

-3.11%↓

GSK

1,851.25

-2.33%↓

STJ

1,195

-2.05%↓

HIK

1,404.5

+1.08%↑

HILS

2,490

-3.11%↓

GSK

1,851.25

-2.33%↓

STJ

1,195

-2.05%↓

HIK

1,404.5

+1.08%↑

HILS

2,490

-3.11%↓

GSK

1,851.25

-2.33%↓

STJ

1,195

-2.05%↓

HIK

1,404.5

+1.08%↑

HILS

2,490

-3.11%↓

GSK

1,851.25

-2.33%↓

STJ

1,195

-2.05%↓

HIK

1,404.5

+1.08%↑

HILS

2,490

-3.11%↓

Kodu・Aktsiate loetelu・AstraZeneca PLC

AstraZeneca PLC

Suletud

SektorTervishoid

13,514 -3.07

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

13514

Max

13632

Põhinäitajad
By Trading Economics
Sissetulek	-177M 2.4B
Müük	312M 16B
P/E Sektori keskmine	28.671 67.147
Aktsiakasum	1.19
Dividenditootlus	1.69
Kasumimarginaal	15.199
Töötajad	96,100
EBITDA	-530M 4.6B

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+18.98% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	1.69% 2.36%
Järgmine tulemuste avaldamine	27. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	-293B 291B
Eelmine avamishind	13517.07
Eelmine sulgemishind	13514

Uudiste sentiment

By Acuity

28%

72%

86 / 347 Pingereas Healthcare

AstraZeneca PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. apr 2026, 16:28 UTC

Tulu

Correction to AstraZeneca Update

29. apr 2026, 15:11 UTC

Tulu

AstraZeneca Plans U.K. Investment as Cancer Drugs Lift Revenue -- Update

29. apr 2026, 06:31 UTC

Tulu

AstraZeneca Gets Revenue Boost From Cancer Drugs

27. märts 2026, 10:04 UTC

Uudisväärsed sündmused

Oil Climbs Higher, Stock Recovery Fades as Doubts Cloud Cease-Fire Hopes

1. mai 2026, 09:31 UTC

Market Talk

AstraZeneca Can Deal With Hit From FDA Cancer Drug Knockback -- Market Talk

29. apr 2026, 10:29 UTC

Market Talk

Tulu

AstraZeneca Beats Expectations, But Focus Is on Busy Pipeline Ahead -- Market Talk

29. apr 2026, 10:06 UTC

Market Talk

Tulu

AstraZeneca, GSK Results Fail to Impress Market -- Market Talk

29. apr 2026, 09:53 UTC

Market Talk

Tulu

AstraZeneca Seems in Fine Health -- Market Talk

29. apr 2026, 06:05 UTC

Tulu

AstraZeneca Says It Remains on Track to Achieve Ambition for 2030, Beyond

29. apr 2026, 06:04 UTC

Tulu

AstraZeneca 1Q Ultomiris Revenue $1.27B, Up 18% at Constant Currency

29. apr 2026, 06:04 UTC

Tulu

AstraZeneca 1Q Farxiga Revenue $2.19B, Down 2% at Constant Currency

29. apr 2026, 06:03 UTC

Tulu

AstraZeneca 1Q Imfinzi Revenue $1.69B, Up 30% at Constant Currency

29. apr 2026, 06:03 UTC

Tulu

AstraZeneca 1Q Tagrisso Revenue $1.83B, Up 5% at Constant Currency

29. apr 2026, 06:02 UTC

Tulu

Analysts Saw AstraZeneca 1Q Core EPS at $2.54

29. apr 2026, 06:01 UTC

Tulu

Analysts Saw AstraZeneca 1Q Revenue at $14.94B

29. apr 2026, 06:01 UTC

Tulu

AstraZeneca Backs 2026 View

29. apr 2026, 06:00 UTC

Tulu

AstraZeneca PLC 1Q Adj EPS $2.58

29. apr 2026, 06:00 UTC

Tulu

AstraZeneca PLC 1Q Rev $15.29B

29. apr 2026, 06:00 UTC

Tulu

AstraZeneca PLC 1Q Pretax Pft $3.91B

29. apr 2026, 06:00 UTC

Tulu

AstraZeneca PLC 1Q Oper Pft $4.25B

29. apr 2026, 06:00 UTC

Tulu

AstraZeneca PLC 1Q Net Pft $3.08B

29. apr 2026, 06:00 UTC

Tulu

AstraZeneca PLC 1Q EPS $1.97

27. apr 2026, 10:48 UTC

Market Talk

AstraZeneca Likely Unaffected by Partner Daiichi Sankyo's Supply Review -- Market Talk

10. apr 2026, 11:57 UTC

Market Talk

AstraZeneca Likely to Increase Spending to Prepare for New Launches -- Market Talk

10. apr 2026, 10:26 UTC

Market Talk

Tulu

AstraZeneca Expected to Reiterate Full-Year Guidance -- Market Talk

2. apr 2026, 09:16 UTC

Market Talk

AstraZeneca Liver Cancer Trial Could Help Imfinzi Peak Sales Beat Views -- Market Talk

27. märts 2026, 10:40 UTC

Market Talk

AstraZeneca Hits Goal in Lung Disease Where Rivals Missed -- Market Talk

27. märts 2026, 10:17 UTC

Market Talk

AstraZeneca Lung Disease Trial Adds Building Block to 2030 Target -- Market Talk

10. veebr 2026, 14:41 UTC

Tulu

Kuumad aktsiad

BP, Ferrari, TSMC: Global Earnings in Focus -- WSJ

10. veebr 2026, 13:18 UTC

Tulu

Kuumad aktsiad

Ferrari, BP, TSMC: Global Earnings in Focus -- WSJ

Võrdlus sarnastega

Hinnamuutus

AstraZeneca PLC Prognoos

Hinnasiht

By TipRanks

18.98% tõus

12 kuu keskmine prognoos

Keskmine 16,076.92 GBX 18.98%

Kõrge 18,600 GBX

Madal 11,300 GBX

Põhineb 15 Wall Streeti analüütiku instrumendi AstraZeneca PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

15 ratings

Osta

Hoia

Müü

Põhineb 15 analüütiku instrumendi AstraZeneca PLC aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

86 / 347 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.